CSI CRF-TCT Satellite Symposium

Optimizing Outcomes in Calcific Cardiovascular Disease.

View email in your browser

SATELLITE SYMPOSIUM:


Optimizing Outcomes in Calcific Cardiovascular Disease: Real-World Techniques with the Diamondback 360® Orbital Atherectomy System


Join us for a live-streamed symposium featuring an expert panel discussion on a complex case recording that shares insights on techniques and tips to streamline treatment with the Diamondback 360 Orbital Atherectomy System.

Thursday, November 4
10:00am EST

Moderators:

Jasvindar Singh, MD, Nicholas Van Meigham, MD


Panelists:

Emmanouil Brilakis, MD, Kevin Croce, MD, Michael Kim, MD, Ki Park, MD

VIEW LIVESTREAM HERE

Your Single Solution for Severe Calcium. 
See how Diamondback 360 OAS sands and fractures with one device.

EXPLORE OUR FULL PORTFOLIO
Visit our virtual experience to learn more.

EXPLORE OUR PORTFOLIO

This activity is sponsored by CSI.

Indication: The Diamondback 360® Coronary Orbital Atherectomy System (OAS) is a percutaneous orbital atherectomy system indicated to facilitate stent delivery in patients with coronary artery disease (CAD) who are acceptable candidates for PTCA or stenting due to de novo, severely calcified coronary artery lesions. Contraindications: The OAS is contraindicated when the ViperWire Advance® Coronary guide wire cannot pass across the coronary lesion or the target lesion is within a bypass graft or stent. The OAS is contraindicated when the patient is not an appropriate candidate for bypass surgery, angioplasty, or atherectomy therapy, or has angiographic evidence of thrombus, or has only one open vessel, or has angiographic evidence of significant dissection at the treatment site and for women who are pregnant or children. Warnings/Precautions: Performing treatment in excessively tortuous vessels or bifurcations may result in vessel damage; The OAS was only evaluated in severely calcified lesions, a temporary pacing lead may be necessary when treating lesions in the right coronary and circumflex arteries; On-site surgical back-up should be included as a clinical consideration; Use in patients with an ejection fraction (EF) of less than 25% has not been evaluated. See the instructions for use before performing Diamondback 360 coronary orbital atherectomy procedures for detailed information regarding the procedure, indications, contraindications, warnings, precautions, and potential adverse events.

Caution: Federal law (USA) restricts these devices to sale by, or on the order of, a physician.

1225 Old Hwy 8 NW
St. Paul, MN 55112

T: 651-259-1600
     877-274-0901

F: 612-677-3355
    www.csi360.com

CSI, Diamondback 360 and ViperWire Advance are registered trademarks of Cardiovascular Systems, Inc. ©2021 Cardiovascular Systems, Inc. EN-XXXX.A 1021